A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Early Breast Cancer
Interventions: BIOLOGICAL: PF-05280014|DRUG: Taxotere®|DRUG: Paraplatin®|BIOLOGICAL: Trastuzumab-EU|DRUG: Taxotere®|DRUG: Paraplatin®
Sponsor: Pfizer